| Abstrakt: |
Objective: Whereas in the treatment of rheumatoid arthritis much evidence exists on the effects of current pharmacologic treatment on clinical outcomes, little is known about the effects on patient‐reported outcomes. This systematic review aims to evaluate the effects of disease‐modifying antirheumatic drugs (DMARDs) on the patient‐relevant domains of pain, fatigue, activity limitation, overall emotional and physical health impact, and work/school/housework ability and productivity. Methods: A literature search was conducted to identify randomized controlled trials wherein registered DMARDs were compared with placebo or methotrexate and reported the effects on patient‐reported outcomes included in the International Consortium of Health Outcomes Measurement standard set for inflammatory arthritis. Random effects meta‐analyses using the standardized mean differences of change scores as the effect measure were performed for the domains of pain, fatigue, and activity limitation, comparing DMARDs with placebo and methotrexate. The other 2 domains were presented narratively. Results: Across the 5 domains, 69 records belonging to 52 studies were identified. All meta‐analyses showed a decrease of burden when DMARDs were compared with placebo (standardized mean differences [95% confidence interval] in pain −0.80 [−0.99, −0.61], fatigue −0.48 [−0.64, −0.32], and activity limitation −0.56 [− 0.63, −0.49]) and when compared with methotrexate (−0.55 [−0.70, −0.41), −0.44 [−0.55, −0.33], and − 0.37 [−0.44, −0.30], respectively). Conclusion: DMARDs decrease the burden in all the domains that are relevant to patients. Effect sizes may be influenced by DMARD type. Therefore, in the decision for rheumatoid arthritis treatment, patient‐reported outcomes should be taken into account. [ABSTRACT FROM AUTHOR] |
Plný text